United Front International
No Result
View All Result
Monday, October 2, 2023
  • Login
  • Register
  • Home
  • US
  • World
  • Politics
  • Health and Wellness
  • Videos
  • Be in the Know
  • ShopNew
Contact us
United Front International
  • Home
  • US
  • World
  • Politics
  • Health and Wellness
  • Videos
  • Be in the Know
  • ShopNew

No products in the cart.

No Result
View All Result
United Front International
No Result
View All Result
Home Be in the Know

New breast cancer drug ‘reduces risk of disease progression or death’

AstraZeneca hails ‘groundbreaking’ results of Enhertu study

by admin
September 20, 2021
in Be in the Know
New breast cancer drug ‘reduces risk of disease progression or death’

Breast cancer drug ‘found to reduce risk of disease progression’

Share on FacebookShare on Twitter

The Independent
Peter Stubley

A new breast cancer drug reduces the risk of death or disease progression by 72 percent compared to an existing treatment, AstraZeneca has announced.

The British pharmaceutical firm said the results of its trial of Enhertu were “groundbreaking” and showed “a strong trend towards improved overall survival.”

Three-quarters of patients showed no progression in their disease after 12 months compared to 34.1 percent of those treated with trastuzumab emtansine (T-DM1), while progression-free survival was improved from 7.2 months to 25.1 months.

Nearly all Enhertu patients were alive after 12 months (94.1 percent), compared to 85.9 percent of T-DM1 patients.

The phase 3 trial, which compared Enhertu’s performance against trastuzumab emtansine as a treatment for HER2-positive metastatic breast cancer, involved around 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America.

Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, said: “Today’s results are ground-breaking.

“These unprecedented data represent a potential paradigm shift in the treatment of HER2-positive metastatic breast cancer, and illustrate the potential for Enhertu to transform more patient lives in earlier treatment settings.”

Javier Cortes, from the International Breast Cancer Centre in Barcelona, said patients with previously treated HER2-positive metastatic breast cancer will typically experience disease progression in less than a year with available HER2-directed treatments.

He said the “high and consistent benefit” seen across efficacy endpoints and key subgroups of patients receiving Enhertu is “remarkable and supports the potential of Enhertu to become the new standard of care for those who have previously been treated for HER2-positive metastatic breast cancer”.

Ken Takeshita, global head of R&D at Daiichi Sankyo, said: “These landmark data will form the basis of our discussions with global health authorities to potentially bring Enhertu to patients with previously treated HER2-positive metastatic breast cancer as a more effective treatment option as soon as possible.”

While breast cancer survival rates have doubled over the last four decades in the UK, every year around 11,500 women and 85 men die from the disease.

The Breast Cancer Now charity, which offers support and information on the disease, welcomed the results of the trial as “incredibly promising”.

Dr. Kotryna Temcinaite, senior research communications manager, said: “It is fantastic to see that trastuzumab deruxtecan (Enhertu) could give hundreds of people with HER2 positive incurable secondary breast cancer the chance of more time before their disease progresses.

“We now hope that further research will show whether this treatment could also offer patients precious extra time to live and be there for more moments that matter. Anyone looking for support and information can speak to Breast Cancer Now’s expert nurses by calling our free Helpline on 0808 800 6000.”

This article was amended on 19 September 2021 to remove the following sentence: ‘However, AstraZeneca warned that the analysis is “not yet mature and is not statistically significant”.’ That warning was only referring to overall survival analysis, not the study as a whole.

Related

ShareTweetSendSend

Related Posts

In this undated photo 14-year-old Emmett L.Till from Chicago, is shown. (AP Photo, File)
US

For Emmett Till’s family, national monument proclamation cements his inclusion in the American story

July 26, 2023
CNN Beaten and abandoned in the desert -- migrants stranded at Tunisian border
Videos

Beaten and abandoned in the desert – migrants stranded at Tunisian border

July 25, 2023
President Joe Biden walks to his motorcade as he leaves Holy Trinity Catholic Church in the Georgetown section of Washington, after attending Mass, Saturday, July 22, 2023. (AP Photo/Manuel Balce Ceneta)
US

Biden will establish a national monument honoring Emmett Till, the Black teen lynched in Mississippi

July 23, 2023
US First Lady Jill Biden speaks during a Fourth of July event on the South Lawn of the White House in Washington, DC, US, on Tuesday, July 4, 2023. Ting Shen/Bloomberg/Getty Images
US

Jill Biden to travel to Paris to commemorate US rejoining UNESCO after Trump exit

July 22, 2023
Tony Bennett performs at Royal Albert Hall in London in 2017.Samir Hussein / WireImage file
Videos

Tony Bennett dead at 96: A look at his life and legacy

July 22, 2023
Iran's police forces stand on a street during the revival of the morality police in Tehran on Sunday. (Wana News Agency/Reuters)
Videos

The head of police in Iran announced the revival of the morality police’s hijab patrols

July 18, 2023

My Cart

No Content Available

Categories

  • Be in the Know
  • Health and Wellness
  • Politics
  • US
  • Videos
  • World

UnitedFrontIntl Store

My Account & Ordering
Cart
Checkout
Track My Order
Refund and Returns Policy
Privacy Policy
FAQs

Site Navigation

  • Home
  • Advertise
  • Contact Us
  • Jobs
  • About Us
  • Shipping Policy

Links

CNBC
Reuters

The New York Times
The Washington Post


Your tax-deductible gift is vital and will help us fund and maintain our website to bring you current news and information on a daily basis. Thank you in advance.

© 2022 United Front Intl

No Result
View All Result
  • Home
  • US
  • World
  • Politics
  • Health and Wellness
  • Videos
  • Be in the Know
  • Contact Us
  • Advertisement
  • Shop

© 2022 United Front Intl

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In